Aralez Bio

We have invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Our proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, with water as the only byproduct. To learn more, visit us at www.aralezbio.com Aralez Bio is a proud member of Cyclotron Road.

http://www.aralezbio.com

11-50 employees

Growth Trajectory

Aralez Bio demonstrates growth potential through expanding its biocatalytic platform to unlock new amino acid scaffolds and stereoisomers, including the development of cyclic amino acids and compounds with quaternary centers. Investment in scaling up production from milligram to kilogram scales and improving their enzyme platform suggests further market expansion and increased product offerings. Their focus on combating disease and creating eco-friendly consumer products indicates a diversification of market applications.

Technical Challenges

Engineering enzymes for previously intractable tryptophan analogues.

Ensuring high purity and enantiopurity of synthesized amino acids.

Developing novel amino acid analogs with fine-tuned properties.

Scaling protein expression from bench to fermentation tanks.

Expanding aromatic repertoire to include phenol and naphthol sidechains.

Tech Stack

EnzymesEnzyme PlatformFermentationBiocatalysisTryptophan Synthase (TrpB)Protein EngineeringHPLCNMRHigh-throughput screeningAutomationHigh-Density Fermentation

Team Size

Manufacturing team

Research and Development team

Quality Control team

Scale-up team

Key Risks

Reliance on enzyme-based manufacturing processes may be vulnerable to unforeseen technical challenges or scalability issues.

The market for noncanonical amino acids may face regulatory hurdles or shifts in demand from pharmaceutical and biotech customers.

Maintaining high purity and enantiopurity in synthesized amino acids could pose ongoing technical challenges.

Traditional noncanonical amino acid manufacture could become more efficient, eroding Aralez Bio's competitive advantage.

Dependence on key partnerships could present risks if those relationships falter or shift priorities.

Opportunities

Leverage their proprietary enzymatic platform to develop a wider range of novel noncanonical amino acids, expanding their product catalog.

Expand partnerships with pharmaceutical and biotech companies to provide API starting materials and custom synthesis services.

Capitalize on the increasing demand for sustainable and cost-efficient manufacturing processes in the chemical industry.

Explore the use of noncanonical amino acids in new applications, such as eco-friendly consumer products and diagnostics.

Enhance the enzyme platform through directed evolution and protein engineering to improve efficiency and reduce costs.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes